Research: 2015–2019
🐀 = animal study 🧬 = genetics focus 📚 = systematic review / meta-analysis
All periods: 2020–present | 2015–2019 | 2010–2014 | 2000–2009 | 1942–1999
Jump to: 2018 | 2017 | 2016 | 2015
2019
Alcántara Montero A, Müller-Arteaga C. 5-alpha reductase inhibitors: new evidences on benefits and harms beyond benign prostatic hyperplasia. Inhibidores de la 5-alfa reductasa: nuevas evidencias sobre los beneficios y los daños más allá de la hiperplasia benigna de próstata. Actas Urol Esp. 2019. doi:10.1016/j.acuro.2018.05.003 • PubMed
🐀 Alkahtane AA, Albasher G, Al-Sultan NK, et al. Long-term treatment with finasteride induces apoptosis and pathological changes in female mice. Hum Exp Toxicol. 2019. doi:10.1177/0960327119842195 • PubMed
Andy G, John M, Mirna S, et al. Controversies in the treatment of androgenetic alopecia: the history of finasteride. Dermatol Ther. 2019. doi:10.1111/dth.12647 • PubMed
🐀 Baig MS, Kolasa-Wołosiuk A, Pilutin A, et al. Finasteride-induced inhibition of 5α-reductase type 2 could lead to kidney damage-animal, experimental study. Int J Environ Res Public Health. 2019. doi:10.3390/ijerph16101726 • PubMed
🐀 Bartolomé I, Llidó A, Darbra S, Pallarès M. Early postnatal allopregnanolone levels alteration and adult behavioral disruption in rats: implication for drug abuse. Neurobiol Stress. 2019. doi:10.1016/j.ynstr.2019.100208 • PubMed
Bortnick EM, Simma-Chiang V, Kaplan SA. Long-term consequences of medical therapy for benign prostatic hyperplasia. Rev Urol. 2019. PubMed • PMC full text
Catalano A, Martino G, Bellone F, et al. Neuropsychological assessment in elderly men with benign prostatic hyperplasia treated with dutasteride. Clin Drug Investig. 2019 Jan. Erratum in: Clin Drug Investig. 2018 Nov 26. doi:10.1007/s40261-018-0720-7 • PubMed
Coskuner ER, Ozkan B, Culha MG. Sexual problems of men with androgenic alopecia treated with 5-alpha reductase inhibitors. Sex Med Rev. 2019. doi:10.1016/j.sxmr.2018.07.003 • PubMed
🐀 Diviccaro S, Giatti S, Borgo F, et al. Treatment of male rats with finasteride, an inhibitor of 5alpha-reductase enzyme, induces long-lasting effects on depressive-like behavior, hippocampal neurogenesis, neuroinflammation and gut microbiota composition. Psychoneuroendocrinology. 2019. doi:10.1016/j.psyneuen.2018.09.021 • PubMed
Diviccaro S, Melcangi RC, Giatti S. Post-finasteride syndrome: an emerging clinical problem. Neurobiol Stress. 2019. doi:10.1016/j.ynstr.2019.100209 • PubMed
Fang Q, Chen P, Du N, Nandakumar KS. Analysis of data from breast diseases treated with 5-alpha reductase inhibitors for benign prostatic hyperplasia. Clin Breast Cancer. 2019. doi:10.1016/j.clbc.2019.04.006 • PubMed
🐀 Fanni S, Scheggi S, Rossi F, et al. 5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction. Neurobiol Dis. 2019. doi:10.1016/j.nbd.2018.09.018 • PubMed
🧬 Ghassemi M, Ghaffarpour GH, Ghods S. The effect of GGC and CAG repeat polymorphisms on the androgen receptor gene in response to finasteride therapy in men with androgenetic alopecia. J Res Med Sci. 2019. doi:10.4103/jrms.JRMS_27_19 • PubMed
🐀 Godar SC, Cadeddu R, Floris G, et al. The steroidogenesis inhibitor finasteride reduces the response to both stressful and rewarding stimuli. Biomolecules. 2019. doi:10.3390/biom9110749 • PubMed
Gray SL, Semla TP. Post-finasteride syndrome. BMJ. 2019. doi:10.1136/bmj.l5047 • PubMed
Haber RS, Gupta AK, Epstein E, Carviel JL, Foley KA. Finasteride for androgenetic alopecia is not associated with sexual dysfunction: a survey-based, single-centre, controlled study. J Eur Acad Dermatol Venereol. 2019. doi:10.1111/jdv.15548 • PubMed
Kaczmarek IA, Prost ME, Wasyluk J. Clinical risk factors associated with intraoperative floppy iris syndrome: a prospective study. Int Ophthalmol. 2019. doi:10.1007/s10792-018-0840-3 • PubMed
🐀 Kilic S, Kolukcu E, Erdemir F, Benli I, Arici A. The effects of oral 5-alpha reductase inhibitors on penile intracavernosal pressures and penile morphology in rat model. Urology J. 2019. doi:10.22037/uj.v0i0.4164 • PubMed
Kjærulff TM, Ersbøll AK, Green A, et al. Finasteride use and risk of male breast cancer: a case-control study using individual-level registry data from Denmark, Finland, and Sweden. Cancer Epidemiol Biomarkers Prev. 2019 May. doi:10.1158/1055-9965.EPI-18-0904 • PubMed
🐀 🧬 Kolasa-Wołosiuk A, Tarnowski M, Baranowska-Bosiacka I, Chlubek D, Wiszniewska B. Antioxidant enzyme expression of mRNA and protein in the epididymis of finasteride-treated male rat offspring during postnatal development. Arch Med Sci. 2019 May. doi:10.5114/aoms.2017.68528 • PubMed • PMC full text
Lai SW, Lai HC, Lin CL, Liao KF. Finasteride use and acute pancreatitis in Taiwan. J Clin Pharmacol. 2015. doi:10.1002/jcph.462 • PubMed
📚 Lee S, Lee YB, Choe SJ, Lee WS. Adverse sexual effects of treatment with finasteride or dutasteride for male androgenetic alopecia: a systematic review and meta-analysis. Acta Derm Venereol. 2019. doi:10.2340/00015555-3035 • PubMed
Lee SG, Park PJ, Lee SR, et al. Influence of postoperative finasteride therapy on recurrence of gynecomastia after mastectomy in men taking finasteride for alopecia. Am J Mens Health. 2019 Sep-Oct. doi:10.1177/1557988319871423 • PubMed
Maksym RB, Kajdy A, Rabijewski M. Post-finasteride syndrome – does it really exist?. Aging Male. 2019. doi:10.1080/13685538.2018.1548589 • PubMed
🐀 Maldarine JS, Sanches BDA, Cabral ÁS, et al. Prenatal exposure to finasteride promotes sex-specific changes in gerbil prostate development. Reprod Fertil Dev. 2019. doi:10.1071/RD19106 • PubMed
Marks DH, Prasad S, De Souza B, Burns LJ, Senna MM. Topical antiandrogen therapies for androgenetic alopecia and acne vulgaris. Am J Clin Dermatol. 2019 Dec 12. doi:10.1007/s40257-019-00493-z • PubMed
🧬 Melcangi RC, Casarini L, Marino M, et al. Altered methylation pattern of the SRD5A2 gene in the cerebrospinal fluid of post-finasteride patients: a pilot study. Endocr Connect. 2019. doi:10.1530/EC-19-0199 • PubMed
Müderrisoglu AE, Becher KF, Madersbacher S, Michel MC. Cognitive and mood side effects of lower urinary tract medication. Expert Opin Drug Saf. 2019 Oct. doi:10.1080/14740338.2019.1652269 • PubMed
🐀 Sasibhushana RB, Shankaranarayana Rao BS, Srikumar BN. Repeated finasteride administration induces depression-like behavior in adult male rats. Behav Brain Res. 2019. doi:10.1016/j.bbr.2019.03.006 • PubMed
Shin YS, Karna KK, Choi BR, Park JK. Finasteride and erectile dysfunction in patients with benign prostatic hyperplasia or male androgenetic alopecia. World J Mens Health. 2019. doi:10.5534/wjmh.180029 • PubMed
🐀 Sung HH, Yu J, Kang SJ, et al. Persistent erectile dysfunction after discontinuation of 5-alpha reductase inhibitor therapy in rats depending on the duration of treatment. World J Mens Health. 2019. doi:10.5534/wjmh.180082 • PubMed
📚 Traish AM, Krakowsky Y, Doros G, Morgentaler A. Do 5α-reductase inhibitors raise circulating serum testosterone levels? A comprehensive review and meta-analysis to explaining paradoxical results. Sex Med Rev. 2019. doi:10.1016/j.sxmr.2018.06.002 • PubMed
Trüeb RM, Régnier A, Dutra Rezende H, Gavazzoni Dias MFR. Post-finasteride syndrome: an induced delusional disorder with the potential of a mass psychogenic illness? Skin Appendage Disord. 2019. doi:10.1159/000497362 • PubMed
Wei L, Lai EC, Kao-Yang YH, Walker BR, MacDonald TM, Andrew R. Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population based cohort study. BMJ. 2019. doi:10.1136/bmj.l1204 • PubMed • PMC full text
Yanagisawa M, Fujimaki H, Takeda A, Nemoto M, Sugimoto T, Sato A. Long-term (10-year) efficacy of finasteride in 523 Japanese men with androgenetic alopecia. Clin Res Trials. 2019;5:1-5. doi:10.15761/CRT.1000273
📚 Zakhem GA, Goldberg JE, Motosko CC, Cohen BE, Ho RS. Sexual dysfunction in men taking systemic dermatologic medication: a systematic review. J Am Acad Dermatol. 2019. doi:10.1016/j.jaad.2019.03.043 • PubMed
📚 Zakhem GA, Motosko CC, Mu EW, Ho RS. Infertility and teratogenicity after paternal exposure to systemic dermatologic medications: a systematic review. J Am Acad Dermatol. 2019 Apr. doi:10.1016/j.jaad.2018.09.031 • PubMed
📚 Zhou Z, Cui Y, Wu J, Ding R, Cai T, Gao Z. Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia. BMC Urol. 2019 Mar 11. doi:10.1186/s12894-019-0446-8 • PubMed • PMC full text
📚 Zhou Z, Song S, Gao Z, Wu J, Ma J, Cui Y. The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis. Clin Interv Aging. 2019. doi:10.2147/CIA.S192435 • PubMed
2018
Almohanna HM, Perper M, Tosti A. Safety concerns when using novel medications to treat alopecia. Expert Opin Drug Saf. 2018 Nov;17(11):1115-1128. doi:10.1080/14740338.2018.1533549 | PubMed
AlSaad D, Lee BH, Al-Obaidly S. Finasteride use during pregnancy and early neonatal outcome: a case report. Int J Clin Pharm. 2018;40(4):803-805. doi:10.1007/s11096-018-0661-5 | PubMed
Andrade C. Why odds ratios can be tricky statistics: the case of finasteride, dutasteride, and sexual dysfunction. J Clin Psychiatry. 2018;79(6). doi:10.4088/JCP.18f12641 | PubMed
Antoniou T, Macdonald EM, Yao Z, et al. A population-based study of the risk of osteoporosis and fracture with dutasteride and finasteride. BMC Musculoskelet Disord. 2018;19(1):160. doi:10.1186/s12891-018-2076-9 | PubMed
[⚠️ Co-author KT McVary was 1) a paid consultant for Merck for the MTOPS trial; 2) co-author of a publication on the MTOPS trial; and 3) retained by Merck as an expert for Propecia litigation, as disclosed in this paper] Baas WR, Butcher MJ, Lwin A, et al. A review of the FAERS data on 5-alpha reductase inhibitors: implications for postfinasteride syndrome. Urology. 2018 Oct;120:143-149. doi:10.1016/j.urology.2018.06.022 | PubMed
[Comment] Seftel AD. Re: A review of the FAERS data on 5-alpha reductase inhibitors: implications for post-finasteride syndrome. J Urol. 2018. doi:10.1016/j.juro.2018.08.078
🐀 Da Silva MHA, Costa WS, Sampaio FJB, De Souza DB. The corpus cavernosum after treatment with dutasteride or finasteride: a histomorphometric study in a benign prostatic hyperplasia rodent model. Asian J Androl. 2018;20(5):505–510. doi:10.4103/aja.aja_28_18 | PubMed | PMC full text
Ganzer CA, Jacobs AR. Emotional consequences of finasteride: fool’s gold. Am J Mens Health. 2018;12(1):90–95. doi:10.1177/1557988316631624 | PubMed
Giatti S, Diviccaro S, Panzica G, Melcangi RC. Post-finasteride syndrome and post-SSRI sexual dysfunction: two sides of the same coin? Endocrine. 2018;61(2):180-193. doi:10.1007/s12020-018-1593-5 | PubMed
Gupta AK, Carviel J, Gupta MA, Shear NH. Assessing dutasteride-associated sexual dysfunction using the U.S. Food and Drug Administration Adverse Event Reporting System. J Eur Acad Dermatol Venereol. 2018;32(8):1373-1376. doi:10.1111/jdv.14728 | PubMed
Healy D, Le Noury J, Mangin D. Enduring sexual dysfunction after treatment with antidepressants, 5α-reductase inhibitors and isotretinoin: 300 cases. Int J Risk Saf Med. 2018;29(3-4):125-134. doi:10.3233/JRS-180744 | PubMed
📚 Kim JH, Baek MJ, Sun HY, et al. Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: a meta-analysis. PLoS One. 2018;13(10):e0203479. Published 2018 Oct 3. doi:10.1371/journal.pone.0203479 | PubMed
Kosilov K, Kuzina I, Kuznetsov V, . The risk of sexual dysfunction and effectiveness of treatment of benign prostatic hyperplasia with severe lower urinary tract dysfunction with combination of dutasteride and solifenacin. J Sex Med. 2018 Nov. doi:10.1016/j.jsxm.2018.09.011 | PubMed
Lee JY, Cho KS. Effects of 5-alpha reductase inhibitors: new insights on benefits and harms. Curr Opin Urol. 2018;28(3):288–293. doi:10.1097/MOU.0000000000000497 | PubMed
📚 Lee SW, Juhasz M, Mobasher P, Ekelem C, Mesinkovska NA. A systematic review of topical finasteride in the treatment of androgenetic alopecia in men and women. J Drugs Dermatol. 2018;17(4):457–463. Journal site | PubMed
🐀 Li L, Kang YX, Ji XM, et al. Finasteride inhibited brain dopaminergic system and open-field behaviors in adolescent male rats. CNS Neurosci Ther. 2018;24(2):115-125. doi:10.1111/cns.12781
🐀 Maurice-Gélinas C, Deslauriers J, Monpays C, Sarret P, Grignon S. The 5α-reductase inhibitor finasteride increases suicide-related aggressive behaviors and blocks clozapine-induced beneficial effects in an animal model of schizophrenia. Physiol Behav. 2018;191:65–72. doi:10.1016/j.physbeh.2018.03.036 | PubMed
[⚠️ Co-author KT McVary was 1) a paid consultant for Merck for the MTOPS trial; 2) co-author of a publication on the MTOPS trial; and 3) retained by Merck as an expert for Propecia litigation, as disclosed in Baas et al., 2018.] McVary KT, Rogers T, Mahon J, Gupta NK. Is sexual function better preserved after water vapor thermal therapy or medical therapy for lower urinary tract symptoms due to benign prostatic hyperplasia?. J Sex Med. 2018;15(12):1728–1738. doi:10.1016/j.jsxm.2018.10.006 | PubMed
[Comment] Kaplan SA. Re: Is sexual function better preserved after water vapor thermal therapy or medical therapy for lower urinary tract symptoms due to benign prostatic hyperplasia?. J Urol. 2020;101097JU0000000000000985. doi:10.1097/JU.0000000000000985
[⚠️ Funded by Merck] Meijer M, Thygesen LC, Green A, et al. Finasteride treatment and male breast cancer: a register-based cohort study in four Nordic countries. Cancer Med. 2018. doi:10.1002/cam4.1273 • PubMed • PMC full text
Mervis JS, Borda LJ, Miteva M. “Post-finasteride syndrome”: what to tell our female patients? Br J Dermatol. 2018;179(3):785-786. doi:10.1111/bjd.16658 | PubMed
Motofei IG, Rowland DL, Baconi DL, et al. Androgenetic alopecia; drug safety and therapeutic strategies. Expert Opin Drug Saf. 2018 Apr;17(4):407-412. doi:10.1080/14740338.2018.1430765 | PubMed
[⚠️ Authors employed by GSK] [Letter] Ong G, Manyak M, Lulic Z. Letter to the Editor: androgenetic alopecia; drug safety and therapeutic strategies. Expert Opin Drug Saf. 2018 Jun;17(6):651-652. doi:10.1080/14740338.2018.1470744 | PubMed
Rezende HD, Dias MFRG, Trüeb RM. A comment on the post-finasteride syndrome. Int J Trichology. 2018;10(6):255-261. doi:10.4103/ijt.ijt_61_18 | PMC full text
Roehrborn CG, Manyak MJ, Palacios-Moreno JM, et al. A prospective randomised placebo-controlled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int. 2018 Apr;121(4):647-658. doi:10.1111/bju.14057 | PubMed
Rowland DL, Motofei IG, Păunică I, et al. Androgenic alopecia; the risk–benefit ratio of finasteride. J Mind Med Sci. 2018;5(1):1–6. doi:10.22543/7674.51.P16 | Full text (PDF)
Said MA, Mehta A. The impact of 5α-reductase inhibitor use for male pattern hair loss on men’s health. Curr Urol Rep. 2018;19(8):65. doi:10.1007/s11934-018-0814-z | PubMed
Schmutz JL. Dépression et idées suicidaires avec le finastéride [Depression and suicidal thoughts associated with finasteride]. Ann Dermatol Venereol. 2018;145(2):155–156. doi:10.1016/j.annder.2018.01.006 | PubMed
[⚠️ Funded by Giuliani, an Italian pharmaceutical company] Sorbellini E, Pinto D, Marzani B, Rinaldi F. Drug treatment for androgenetic alopecia: first Italian questionnaire survey on what dermatologists think about finasteride. Dermatol Ther (Heidelb). 2018;8(2):259-267. doi:10.1007/s13555-018-0233-6 | PubMed | PMC full text
🐀 🧬 Sun S, Wang YC, Guo K, DU J, Zhou HJ, Ren AJ. [Finasteride inhibits microvascular density and VEGF expression in the seminal vesicle of rats]. Zhonghua Nan Ke Xue. 2018 May;24(5):387-392. Chinese. PubMed
Than JK, Rodriguez K, Khera M. Post-finasteride syndrome: a review of current literature. Curr Sex Health Rep. 2018;10:152-157. doi:10.1007/s11930-018-0163-4
🧬 Traish, AM. The post-finasteride syndrome: clinical manifestation of drug-induced epigenetics due to endocrine disruption. Curr Sex Health Rep. 2018;10:88–103. doi:10.1007/s11930-018-0161-6
[⚠️ Funded by GSK, maker of Avodart (dutasteride)] Tsai TF, Choi GS, Kim BJ, et al. Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia. J Dermatol. 2018 Jul. doi:10.1111/1346-8138.14329 | PubMed | PMC full text
Walf AA, Kaurejo S, Frye CA. Research brief: self-reports of a constellation of persistent antiandrogenic, estrogenic, physical, and psychological effects of finasteride usage among men. Am J Mens Health. 2018;12(4):900-906. doi:10.1177/1557988317750989 | PubMed
Welk B, McArthur E, Ordon M, Dirk J, Dixon S, Garg AX. Risk of rhabdomyolysis from 5-α reductase inhibitors. Pharmacoepidemiol Drug Saf. 2018 Mar;27(3):351-355. doi:10.1002/pds.4383 | PubMed
Zhang Y, Xu J, Jing J, Wu X, Lv Z. Serum levels of androgen-associated hormones are correlated with curative effect in androgenic alopecia in young men. Med Sci Monit. 2018;24:7770-7777. doi:10.12659/MSM.913116
2018 abstracts
Gupta MA, Vujcic B, Sheridan AD, Gupta AK. 0917 Finasteride is associated with a higher odds of obstructive sleep apnea (OSA): results from the US FDA Adverse Events Reporting System (FAERS). Sleep. 2018 Apr;41(Issue suppl_1):A340–A341. doi:10.1093/sleep/zsy061.916
Nguyen LH, Makino A, Namkoong P, Yiannakou Y, Narain K. Finasteride induced clinical ocular toxicity (ARVO Annual Meeting Abstract). Investigative Ophthalmology & Visual Science. 2018 Jul;59(9):2655. Abstract | Poster | Letter from K. Narain on findings
[⚠️ Dr. KT McVary was 1) a paid consultant for Merck for the MTOPS trial; 2) co-author of a publication on the MTOPS trial; and 3) retained by Merck as an expert for Propecia litigation, as disclosed in Baas et al., 2018.] McVary KT. Post-finasteride syndrome: an evaluation of the FAERS data on 5-alpha reductase inhibitors. Fact, fantasy or forget about it? Lecture at: Indiana Urologic Association 2018 Annual Meeting; February 24, 2018; Indianapolis, Indiana. Program (PDF) – see p. 5.
2017
Arif T, Dorjay K, Adil M, Sami M. Dutasteride in androgenetic alopecia: an update. Curr Clin Pharmacol. 2017;12(1):31–35. doi:10.2174/1574884712666170310111125 | PubMed
🧬 Cauci S, Chiriacò G, Cecchin E, et al. Androgen receptor (AR) gene (CAG)n and (GGN)n length polymorphisms and symptoms in young males with long-lasting adverse effects after finasteride use against androgenic alopecia. Sex Med. 2017 Mar;5(1):e61-e71. doi:10.1016/j.esxm.2016.11.001 | PubMed | PMC full text
📚 Corona G, Tirabassi G, Santi D, et al. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis. Andrology. 2017;5(4):671-678. doi:10.1111/andr.12353 | PubMed
🐀 Cumberland AL, Palliser HK, Crombie GK, Walker DW, Hirst JJ. Increased anxiety-like phenotype in female guinea pigs following reduced neurosteroid exposure in utero. Int J Dev Neurosci. 2017;58:50–58. doi:10.1016/j.ijdevneu.2017.02.001 | PubMed
Drobnis EZ, Nangia AK. 5α-reductase inhibitors (5ARIs) and male reproduction. Adv Exp Med Biol. 2017;1034:59–61. doi:10.1007/978-3-319-69535-8_7 | PubMed
Enatsu N, Chiba K, Sumii K, et al. Dutasteride-mediated morphological changes in the genitourinary tract associated with altered expression patterns of the androgen and estrogen receptors in male rats. Andrology. 2017 Mar;5(2):347-353. doi:10.1111/andr.12297 | PubMed
📚 Fertig RM, Gamret AC, Darwin E, Gaudi S. Sexual side effects of 5-α-reductase inhibitors finasteride and dutasteride: A comprehensive review. Dermatol Online J. 2017;23(11). Journal site | PubMed
Fouda AM, Bazeed AM. Hematuria and hematospermia associated with the use of finasteride for the treatment of androgenic alopecia: a case report. Drug Saf Case Rep. 2017 Oct 31;4(1):14. doi:10.1007/s40800-017-0059-7. PubMed | PMC full text
Gandhi J, Weissbart SJ, Smith NL, et al. The impact and management of sexual dysfunction secondary to pharmacological therapy of benign prostatic hyperplasia. Transl Androl Urol. 2017 Apr;6(2):295-304. doi:10.21037/tau.2017.03.57 | PubMed
🐀 🧬 García-García M, Sánchez-Hernández M, García-Hernández MP, García-Ayala A, Chaves-Pozo E. Role of 5α-dihydrotestosterone in testicular development of gilthead seabream following finasteride administration. J Steroid Biochem Mol Biol. 2017;174:48-55. doi:10.1016/j.jsbmb.2017.07.024 | PubMed
Gupta AK, Carviel J, MacLeod MA, Shear N. Assessing finasteride-associated sexual dysfunction using the FAERS database. J Eur Acad Dermatol Venereol. 2017;31(6):1069-1075. doi:10.1111/jdv.14223 | PubMed
Hagberg KW, Divan HA, Fang SC, Nickel JC, Jick SS. Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia. Clin Epidemiol. 2017;9:83‐91. doi:10.2147/CLEP.S124674 | PubMed
Hagberg KW, Divan HA, Nickel JC, Jick SS. Risk of incident antidepressant-treated depression associated with use of 5α-reductase inhibitors compared with use of α-blockers in men with benign prostatic hyperplasia: a population-based study using the Clinical Practice Research Datalink. Pharmacotherapy. 2017;37(5):517‐527. doi:10.1002/phar.1925 | PubMed
📚 Jun JEJ, Kinkade A, Tung ACH, Tejani AM. 5α-reductase inhibitors for treatment of benign prostatic hyperplasia: a systematic review and meta-analysis. Can J Hosp Pharm. 2017;70(2):113-119. doi:10.4212/cjhp.v70i2.1643 | PubMed
Kiguradze T, Temps WH, Yarnold PR, et al. Persistent erectile dysfunction in men exposed to the 5α-reductase inhibitors, finasteride, or dutasteride. PeerJ. 2017;5:e3020. doi:10.7717/peerj.3020 | PubMed
Kuhl, H., Wiegratz, I. Das post-finasterid-Syndrom. Gynäkologische Endokrinologie. 2017;15:153–163. doi:10.1007/s10304-017-0126-2
🐀 Li K, Zhang C, Yang Z, Wang Y, Si H. Evaluation of a novel dry eye model induced by oral administration of finasteride. Mol Med Rep. 2017;16(6):8763–8770. doi:10.3892/mmr.2017.7754 | PubMed
🐀 Litim N, Morissette M, Caruso D, Melcangi RC, Di Paolo T. Effect of the 5α-reductase enzyme inhibitor dutasteride in the brain of intact and parkinsonian mice. J Steroid Biochem Mol Biol. 2017;174:242‐256. doi:10.1016/j.jsbmb.2017.09.021 | PubMed
Melcangi RC, Santi D, Spezzano R, et al. Neuroactive steroid levels and psychiatric and andrological features in post-finasteride patients. J Steroid Biochem Mol Biol. 2017;171:229-235. doi:10.1016/j.jsbmb.2017.04.003 | PubMed
Motofei IG, Rowland DL, Georgescu SR, et al. Post-finasteride adverse effects in male androgenic alopecia: a case report of vitiligo. Skin Pharmacol Physiol. 2017;30(1):42-45. doi:10.1159/000455972 | PubMed
Motofei IG, Rowland DL, Manea M, Georgescu SR, Păunică I, Sinescu I. Safety profile of finasteride: distribution of adverse effects according to structural and informational dichotomies of the mind/brain. Clin Drug Investig. 2017;37(6):511-517. doi:10.1007/s40261-017-0501-8 | PubMed
Ritchie HE, Oakes DJ, Hegedus E, Hill M, Kennedy D. Counselling regarding paternal exposures: Can we do better? Aust N Z J Obstet Gynaecol. 2017 Apr;57(2):162-167. doi:10.1111/ajo.12584 | PubMed
Shanshanwal SJ, Dhurat RS. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: a randomized controlled open-label, evaluator-blinded study. Indian J Dermatol Venereol Leprol. 2017;83(1):47-54. doi:10.4103/0378-6323.188652
Skeldon SC, Macdonald EM, Law MR, et al. The cardiovascular safety of dutasteride. J Urol. 2017 May;197(5):1309-1314. doi:10.1016/j.juro.2016.11.082 | PubMed
🐀 Soni KK, Shin YS, Choi BR, et al. Protective effect of DA-9401 in finasteride-induced apoptosis in rat testis: inositol requiring kinase 1 and c-Jun N-terminal kinase pathway. Drug Des Devel Ther. 2017;11:2969-2979. doi:10.2147/DDDT.S140543 | PubMed
Teichert M, van Puijenbroek E, Stricker BH. Contraindicated use of 5-alpha-reductase inhibitors in women. Br J Clin Pharmacol. 2017;83(2):429-431. doi:10.1111/bcp.13118 | PubMed
Thielke S. The risk of suicidality and depression from 5-α reductase inhibitors. JAMA Intern Med. 2017 May 1;177(5):691-692. doi:10.1001/jamainternmed.2017.0096 | PubMed
Traish AM. Negative impact of testosterone deficiency and 5α-reductase inhibitors therapy on metabolic and sexual function in men. Adv Exp Med Biol. 2017;1043:473-526. doi:10.1007/978-3-319-70178-3_22 | PubMed
Traish A, Haider KS, Doros G, Haider A. Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction. Horm Mol Biol Clin Investig. 2017;30(3). doi:10.1515/hmbci-2017-0015 | PubMed
Trüeb RM. Discriminating in favour of or against men with increased risk of finasteride-related side effects? Exp Dermatol. 2017;26(6):527-528. doi:10.1111/exd.13155 | PubMed
Voznesensky I, Shaw E, DeLay KJ, Yafi F, Hellstrom, WJG. Benign prostatic hyperplasia treatment options and their effects on sexual function. Sexual Medicine Reviews. Jan 2017;5(1):87-102. doi:10.1016/j.sxmr.2016.05.006
Welk B, McArthur E, Ordon M, Anderson KK, Hayward J, Dixon S. Association of suicidality and depression with 5α-reductase inhibitors. JAMA Intern Med. 2017;177(5):683–691. doi:10.1001/jamainternmed.2017.0089 | PubMed
Welk B, McArthur E, Ordon M, Morrow SA, Hayward J, Dixon S. The risk of dementia with the use of 5 alpha reductase inhibitors. J Neurol Sci. 2017;379:109-111. doi:10.1016/j.jns.2017.05.064 | PubMed
2017 abstracts
Ibarra Vilar P, Marín Pérez A, Hernández Peñalver AI, et al. Genitales ambiguos tras toma de finasteride [Ambiguous genitalia after taking finasteride] [Abstract]. Presented at: XXVII Reunión de la Sociedad Ginecológica Murciana: Laparoscopia ginecológica. March 4, 2017; Hospital Comarcal del Noroeste, Caravaca de la Cruz, Spain. Spanish. Content warning: includes a sensitive image of a fetus. Abstract (Spanish) • English translation
2016
Arias-Santiago S, Camacho-Martínez FM. Adverse effects of 5-alpha reductase inhibitor therapy in men with androgenetic alopecia: Is there cause for concern? [Efectos adversos de los inhibidores de la 5-alfa-reductasa en la alopecia androgenética masculina ¿Hay por qué preocuparse?]. Actas Dermosifiliogr. 2016;107(9):709–711. doi:10.1016/j.ad.2016.06.006 | PubMed
🧬 Basaria S, Jasuja R, Huang G, et al. Characteristics of men who report persistent sexual symptoms after finasteride use for hair loss. J Clin Endocrinol Metab. 2016;101(12):4669-4680. doi:10.1210/jc.2016-2726 | PubMed
Santmann J. Letter to the Editor: “Characteristics of men who report persistent sexual symptoms after finasteride use for hair loss.” J Clin Endocrinol Metab. 2017;102(6):2117-2118. doi:10.1210/jc.2016-3491
Bhasin S, Stern E, Basaria S. Response to Letter: “Characteristics of men who report persistent sexual symptoms after finasteride use for hair loss.” J Clin Endocrinol Metab. 2017;102(6):2119-2120. doi:10.1210/jc.2016-3682
Cakir OO, Serefoglu EC. Post-finasteride syndrome: an underestimated phenomenon. Urol Androl Open J. 2017;1(1):e3-e4. doi:10.17140/UAOJ-1-e002 | Full text from journal
Carreño-Orellana N, Moll-Manzur C, Carrasco-Zuber JE, Álvarez-Véliz S, Berroeta-Mauriziano D, Porras-Kusmanic N. Efectos adversos de finasteride: mitos y realidades. Una revisión actualizada [Finasteride adverse effects: an update]. Rev Med Chil. 2016;144(12):1584‐1590. doi:10.4067/S0034-98872016001200010 | PubMed
Chatziralli IP, Peponis V, Parikakis E, Maniatea A, Patsea E, Mitropoulos P. Risk factors for intraoperative floppy iris syndrome: a prospective study. Eye (Lond). 2016 Aug;30(8):1039-44. doi:10.1038/eye.2016.122 | PubMed | PMC full text
Chatziralli IP, Sergentanis TN, Papazisis L, Moschos MM. Risk factors for intraoperative floppy iris syndrome: a retrospective study. Acta Ophthalmol. 2012 Mar;90(2):e152-3. doi:10.1111/j.1755-3768.2011.02132.x | PubMed
Chiriacò G, Cauci S, Mazzon G, Trombetta C. An observational retrospective evaluation of 79 young men with long-term adverse effects after use of finasteride against androgenetic alopecia. Andrology. 2016;4(2):245-250. doi:10.1111/andr.12147 | PubMed | Free full text (Wiley)
🐀 Corbin CJ, Legacki EL, Ball BA, Scoggin KE, Stanley SD, Conley AJ. Equine 5α-reductase activity and expression in epididymis. J Endocrinol. 2016;231(1):23-33. doi:10.1530/JOE-16-0175 | PubMed
📚 Favilla V, Russo GI, Privitera S, et al. Impact of combination therapy 5-alpha reductase inhibitors (5-ARI) plus alpha-blockers (AB) on erectile dysfunction and decrease of libido in patients with LUTS/BPH: a systematic review with meta-analysis. Aging Male. 2016;19(3):175-181. doi:10.1080/13685538.2016.1195361 | PubMed
Fertig R, Shapiro J, Bergfeld W, Tosti A. Investigation of the plausibility of 5-alpha-reductase inhibitor syndrome. Skin Appendage Disord. 2016;2(3-4):120-129. doi:10.1159/000450617 | PubMed
Füllhase C, Schneider MP. 5-alpha-reductase inhibitors and combination therapy. Urol Clin North Am. 2016;43(3):325-336. doi:10.1016/j.ucl.2016.04.003 | PubMed
Garreton AS, Valzacchi GR, Layus O. Post-finasteride syndrome: about 2 cases and review of the literature. Andrology-Open Access. 2016;5(2):170. doi:10.4172/2472-1212.1000170 | Journal site
🐀 Giatti S, Foglio B, Romano S, et al. Effects of subchronic finasteride treatment and withdrawal on neuroactive steroid levels and their receptors in the male rat brain. Neuroendocrinology. 2016;103(6):746-757. doi:10.1159/000442982 | PubMed
Guo M, Heran B, Flannigan R, Kezouh A, Etminan M. Persistent sexual dysfunction with finasteride 1 mg taken for hair loss. Pharmacotherapy. 2016;36(11):1180-1184. doi:10.1002/phar.1837 | PubMed
Gupta AK, Sharma N, Shukla P. Atypical post-finasteride syndrome: a pharmacological riddle. Indian J Pharmacol. 2016;48(3):316–317. doi:10.4103/0253-7613.182898 | PubMed
Hagberg KW, Divan HA, Persson R, Nickel JC, Jick SS. Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink. BMJ. 2016;354:i4823. doi:10.1136/bmj.i4823 | PubMed
[Comment] Gupta NK, McVary KT. Re: Risk of erectile dysfunction associated with use of 5α-reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink. Eur Urol. 2017;72(2):317–318. doi:10.1016/j.eururo.2017.03.043 | PubMed
Hazlehurst JM, Oprescu AI, Nikolaou N, et al. Dual-5α-reductase inhibition promotes hepatic lipid accumulation in man. J Clin Endocrinol Metab. 2016;101(1):103–113. doi:10.1210/jc.2015-2928 | PubMed
📚 Hirshburg JM, Kelsey PA, Therrien CA, Gavino AC, Reichenberg JS. Adverse effects and safety of 5-alpha reductase inhibitors (finasteride, dutasteride): a systematic review. J Clin Aesthet Dermatol. 2016;9(7):56-62. PubMed | PMC full text
Kaplan SA, Lee JY, Meehan AG, Kusek JW. time course of incident adverse experiences associated with doxazosin, finasteride and combination therapy in men with benign prostatic hyperplasia: the MTOPS trial. J Urol. 2016;195(6):1825-1829. doi:10.1016/j.juro.2015.11.065 | PubMed
Kelly Y, Blanco A, Tosti A. Androgenetic alopecia: an update of treatment options. Drugs. 2016 Sep;76(14):1349-64. doi:10.1007/s40265-016-0629-5 | PubMed
📚 La Torre A, Giupponi G, Duffy D, Conca A, Cai T, Scardigli A. Sexual dysfunction related to drugs: a critical review. Part V: α-blocker and 5-ARI drugs. Pharmacopsychiatry. 2016;49(1):3-13. doi:10.1055/s-0035-1565100 PubMed
Lee SS, Yang YW, Tsai TH, et al. 5-alpha-reductase inhibitors and the risk of diabetes mellitus: a nationwide population-based study. Prostate. 2016 Jan;76(1):41-7. doi:10.1002/pros.23097 | PubMed
📚 Liu L, Zhao S, Li F, et al. Effect of 5α-reductase inhibitors on sexual function: a meta-analysis and systematic review of randomized controlled trials. J Sex Med. 2016;13(9):1297-1310. doi:10.1016/j.jsxm.2016.07.006 | PubMed
[Comment] Kaplan SA. Re: Effect of 5α-reductase inhibitors on sexual function: a meta-analysis and systematic review of randomized controlled trials. J Urol. 2018;199(1):8-9. doi:10.1016/j.juro.2017.09.133
🐀 Llidó A, Bartolomé I, Darbra S, Pallarès M. Neonatal finasteride administration decreases dopamine release in nucleus accumbens after alcohol and food presentation in adult male rats. Behav Brain Res. 2016;309:44-50. doi:10.1016/j.bbr.2016.04.047 | PubMed
Maeda T, Kikuchi E, Hasegawa M, et al. A prospective longitudinal survey of erectile function status in symptomatic benign prostatic hyperplasia patients treated with dutasteride. Aging Male. 2016 Jun;19(2):111-6. doi:10.3109/13685538.2016.1156082 | PubMed
Kaplan SA. Re: A prospective longitudinal survey of erectile function status in symptomatic benign prostatic hyperplasia patients treated with dutasteride. J Urol. 2017 Sep;198(3):459. doi:10.1016/j.juro.2017.06.032 | PubMed
🐀 Magri ML, Gottardo MF, Zárate S, et al. Opposite effects of dihydrotestosterone and estradiol on apoptosis in the anterior pituitary gland from male rats. Endocrine. 2016 Mar;51(3):506-16. doi:10.1007/s12020-015-0719-2 | PubMed
Molina-Leyva A, Caparros-Del Moral I, Gomez-Avivar P, Alcalde-Alonso M, Jimenez-Moleon JJ. Psychosocial impairment as a possible cause of sexual dysfunction among young men with mild androgenetic alopecia: a cross-sectional crowdsourcing web-based study. Acta Dermatovenerol Croat. 2016;24(1):42-48. Europe PMC | Journal site
Motofei IG, Rowland DL, Georgescu SR, et al. Finasteride adverse effects in subjects with androgenic alopecia: A possible therapeutic approach according to the lateralization process of the brain. J Dermatolog Treat. 2016;27(6):495-497. doi:10.3109/09546634.2016.1161155 | PubMed
Motofei IG, Rowland DL, Georgescu SR, Tampa M, Baleanu BC, Paunica S. Are hand preference and sexual orientation possible predicting factors for finasteride adverse effects in male androgenic alopecia? Exp Dermatol. 2016;25(7):557-558. doi:10.1111/exd.13003 | PubMed
Mysore V, Shashikumar BM. Guidelines on the use of finasteride in androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2016;82(2):128–134. doi:10.4103/0378-6323.177432 | PubMed
Oelke M, Martinelli E. [Pharmacological treatment of benign prostatic hyperplasia]. Urologe A. 2016;55(1):81-94; quiz 95-96. doi:10.1007/s00120-015-0011-3 | PubMed
Paunica S, Giurgiu M, Vasilache A, Paunica I, Motofei I, Vasilache A, Dumitriu HT, Dumitriuv AS. Finasteride adverse effects and post-finasteride syndrome; implications for dentists. Journal of Mind and Medical Sciences. 2016;3(1):71-79. https://scholar.valpo.edu/jmms/vol3/iss1/9/. Accessed May 14, 2021.
Pirozzi Farina F, Pischedda A. Comments concerning the real risk of sexual adverse events secondary to the use of 5-ARIs. Arch Ital Urol Androl. 2016;87(4):312-316. doi:10.4081/aiua.2015.4.312 | PubMed
Seale LR, Eglini AN, McMichael AJ. Side effects related to 5 α-reductase inhibitor treatment of hair loss in women: a review. J Drugs Dermatol. 2016;15(4):414-419. Journal site | PubMed
Soggiu A, Piras C, Greco V, et al. Exploring the neural mechanisms of finasteride: a proteomic analysis in the nucleus accumbens. Psychoneuroendocrinology. 2016;74:387–396. doi:10.1016/j.psyneuen.2016.10.001 | PubMed
Sonthalia S, Sahaya K, Arora R, et al. Nocebo effect in dermatology. Indian J Dermatol Venereol Leprol. 2015 May-Jun;81(3):242-50. doi:10.4103/0378-6323.155573 | PubMed
Tsunemi Y, Irisawa R, Yoshiie H, et al; ARI114264 Study Group. Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia. J Dermatol. 2016 Sep;43(9):1051-8. doi:10.1111/1346-8138.13310 | PubMed
Unger JM, Till C, Thompson IM, et al. Long-term consequences of finasteride vs placebo in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2016;108(12). doi:10.1093/jnci/djw168 | PubMed
Welliver C, Essa A. Sexual side effects of medical and surgical benign prostatic hyperplasia treatments. Urol Clin North Am. 2016;43(3):393–404. doi:10.1016/j.ucl.2016.04.010 | PubMed
🧬 Wu M, Yu Q, Li Q. Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases. Oncotarget. 2016;7(50):82074-82084. doi:10.18632/oncotarget.12617 | PubMed
Zhang C, Li K, Yang Z, Wang Y, Si H. The effect of the aqueous extract of Bidens pilosa L. on androgen deficiency dry eye in rats. Cell Physiol Biochem. 2016;39(1):266-77. doi:10.1159/000445622 | PubMed
2016 abstracts
Butcher M, Baas W, Lwin A, et al. MP89-08 Post-finasteride syndrome: real or imagined? Journal of Urology. 2016;195(4S):e1139. doi:10.1016/j.juro.2016.02.2469
Fiuk J, Butcher M, Kohler T, McVary K. 133 Female post-finasteride syndrome: It’s not just a man’s world. Journal Sex Med. 2016 May 1;13(5, Suppl 1):S62-S63. doi:10.1016/j.jsxm.2016.02.139
Georgescu SR, Paunica S, Tampa M, et al. 200 Uncommon finasteride side effects in male androgenic alopecia. J Invest Dermatol. ESDR 2016 Annual Meeting Abstract Supplement: Hair and Other Adnexal Structures. 2016 Sep 1;136(9, Suppl 2):S195. doi:10.1016/j.jid.2016.06.219.
Lwin A, Butcher M, Holland B, et al. 054 Post finasteride syndrome: Guess who—demographics from FDA database. J Sex Med. 2016;13(5, Supplement 1):S26. doi:10.1016/j.jsxm.2016.02.057
2015
Ali AK, Heran BS, Etminan M. Persistent sexual dysfunction and suicidal ideation in young men treated with low-dose finasteride: a pharmacovigilance study. Pharmacotherapy. 2015;35(7):687-695. doi:10.1002/phar.1612 | PubMed
📚 Belknap SM, Aslam I, Kiguradze T, et al. Adverse event reporting in clinical trials of finasteride for androgenic alopecia: a meta-analysis. JAMA Dermatol. 2015;151(6):600-606. doi:10.1001/jamadermatol.2015.36 | PubMed
Patients treated for male pattern hair with finasteride show, after discontinuation of the drug, altered levels of neuroactive steroids in cerebrospinal fluid and plasma. J Steroid Biochem Mol Biol. 2015 Feb;146:74-9. doi: 10.1016/j.jsbmb.2014.03.012. Epub 2014 Apr 6. Erratum in: J Steroid Biochem Mol Biol. 2023 Sep 27;234:106405. PMID: 24717976.
Caruso D, Abbiati F, Giatti S, et al. Patients treated for male pattern hair loss with finasteride show, after discontinuation of the drug, altered levels of neuroactive steroids in cerebrospinal fluid and plasma. J Steroid Biochem Mol Biol. 2015;146:74-79. doi:10.1016/j.jsbmb.2014.03.012 | PubMed
Chou CH, Lin CL, Lin MC, Sung FC, Kao CH. 5α-Reductase inhibitors increase acute coronary syndrome risk in patients with benign prostate hyperplasia. J Endocrinol Invest. 2015 Jul;38(7):799-805. doi:10.1007/s40618-015-0263-1 | PubMed
Descazeaud A, de La Taille A, Giuliano F, Desgrandchamps F, Doridot G. [Negative effects on sexual function of medications for the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia]. Prog Urol. 2015;25(3):115-127. doi:10.1016/j.purol.2014.12.003 | PubMed
Ganzer CA, Jacobs AR, Iqbal F. Persistent sexual, emotional, and cognitive impairment post-finasteride: a survey of men reporting symptoms. Am J Mens Health. 2015;9(3):222-228. doi:10.1177/1557988314538445 | PubMed
Glina S, Roehrborn CG, Esen A, et al. Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride. J Sex Med. 2015;12(1):129-138. doi:10.1111/jsm.12714 | PubMed
🐀 Horvath K, Vultur F, Simon V, Voidazan S, Mühlfay G. Research on intraoperative iris behavior in rabbits treated with tamsulosin and finasteride. Hippokratia. 2015 Jan-Mar;19(1):20-4. PubMed | PMC full text
Hsieh TF, Yang YW, Lee SS, t al. Use of 5-alpha-reductase inhibitors did not increase the risk of cardiovascular diseases in patients with benign prostate hyperplasia: a five-year follow-up study. PLoS One. 2015 Mar 24;10(3):e0119694. doi:10.1371/journal.pone.0119694 | PubMed | PMC full text
Irwig MS. Safety concerns regarding 5α reductase inhibitors for the treatment of androgenetic alopecia. Curr Opin Endocrinol Diabetes Obes. 2015;22(3):248-253. doi:10.1097/MED.0000000000000158 | PubMed
Kang DW, Jeong HG, Kim HR, et al. Finasteride induced cerebral venous thrombosis. Journal of the Korean Neurological Association. 2015;33(3):238-240. PDF at ResearchGate
🐀 Kolasa-Wolosiuk A, Misiakiewicz-Has K, Baranowska-Bosiacka I, Gutowska I, Wiszniewska B. Androgen levels and apoptosis in the testis during postnatal development of finasteride-treated male rat offspring. Folia Histochem Cytobiol. 2015;53(3):236-48. doi:10.5603/fhc.a2015.0025 | PubMed
Lee MR, Loux-Turner JR, Oliveira K. Evaluation of the 5α-reductase inhibitor finasteride on reproduction and gonadal development in medaka, Oryzias latipes. Gen Comp Endocrinol. 2015 May 15;216:64-76. doi:10.1016/j.ygcen.2015.04.008 | PubMed
Lin WL, Hsieh YW, Lin CL, Sung FC, Wu CH, Kao CH. A population-based nested case-control study: the use of 5-alpha-reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia. Clin Endocrinol. 2015 Apr;82(4):503-8. doi:10.1111/cen.12599 | PubMed
🐀 Litim N, Bourque M, Al Sweidi S, Morissette M, Di Paolo T. The 5α-reductase inhibitor dutasteride but not finasteride protects dopamine neurons in the MPTP mouse model of Parkinson’s disease. Neuropharmacology. 2015;97:86‐94. doi:10.1016/j.neuropharm.2015.05.015 | PubMed
🐀 Livingstone DE, Barat P, Di Rollo EM, et al. 5α-Reductase type 1 deficiency or inhibition predisposes to insulin resistance, hepatic steatosis, and liver fibrosis in rodents. Diabetes. 2015;64(2):447-458. doi:10.2337/db14-0249 | PubMed
Mirela M, Ioana P, Maria PG, Mihnea MC. Finasteride side effects and post-finasteride syndrome in male androgenic alopecia. Journal of Mind and Medical Sciences. 2015;2(2):142–149. Open access
Mladenović D, Petronijević N, Stojković T, et al. Finasteride has regionally different effects on brain oxidative stress and acetylcholinesterase activity in acute thioacetamide-induced hepatic encephalopathy in rats. PLoS One. 2015 Aug 4;10(8):e0134434. doi:10.1371/journal.pone.0134434 | PubMed
Moore TJ. Finasteride and the uncertainties of establishing harms. JAMA Dermatol. 2015 Jun;151(6):585-6. doi:10.1001/jamadermatol.2015.37 | PubMed
Narasimhalu CR. Randomized questionnaire based case-control research study on evaluation of sexual function in Indian patients taking oral finasteride for androgenetic alopecia. Dermatol Ther (Heidelb). 2015;5(4):231-234. doi:10.1007/s13555-015-0084-3 | PubMed
Nasiri M, Nikolaou N, Parajes S, et al. 5α-reductase type 2 regulates glucocorticoid action and metabolic phenotype in human hepatocytes. Endocrinology. 2015;156(8):2863–2871. doi:10.1210/en.2015-1149 | PubMed
🐀 Pallarès M, Llidó A, Mòdol L, Vallée M, Darbra S. Finasteride administration potentiates the disruption of prepulse inhibition induced by forced swim stress. Behav Brain Res. 2015;289:55-60. doi:10.1016/j.bbr.2015.04.023 • PubMed
Pérez-Cotapos ML, Lobos A. Finasteride: mitos y verdades [Finasteride: myths and truths]. 2015. Rev Chilena Dermatol 2015;31(1):83-87. Spanish. Full text | Global Index Medicus
Perez-Mora N, Velasco C, Bermüdez F. Oral finasteride presents with sexual-unrelated withdrawal in long-term treated androgenic alopecia in men. Skinmed. 2015;13(3):179-183. PubMed
Stojanović N, Ignjatović I, Djenić N, Bogdanović D. Adverse effects of pharmacological therapy of benign prostatic hyperplasia on sexual function in men. Srp Arh Celok Lek. 2015;143(5-6):284–289. doi:10.2298/sarh1506284s | PubMed
Tian HL, Zhao CX, Wu HY, et al. Finasteride reduces microvessel density and expression of vascular endothelial growth factor in renal tissue of diabetic rats. Am J Med Sci. 2015 Jun. 10.1097/MAJ.0000000000000451 • PubMed
Traish AM. The impact of the 5α-reductase inhibitors (5α-RIs) on male sexual function and psychological well-being. Curr Sex Health Rep. 2015;7:210–219. doi:10.1007/s11930-015-0061-y
Traish AM, Haider KS, Doros G, Haider A. Finasteride, not tamsulosin, increases severity of erectile dysfunction and decreases testosterone levels in men with benign prostatic hyperplasia. Horm Mol Biol Clin Investig. 2015;23(3):85-96. doi:10.1515/hmbci-2015-0015 | PubMed
Traish AM, Melcangi RC, Bortolato M, Garcia-Segura LM, Zitzmann M. Adverse effects of 5α-reductase inhibitors: What do we know, don’t know, and need to know? Rev Endocr Metab Disord. 2015;16(3):177-198. doi:10.1007/s11154-015-9319-y | PubMed
Bibliographies: 2020–present | 2015–2019 | 2010–2014 | 2000–2009 | 1942–1999